BUZZ-Leerink Partners lowers PT on drugmaker Regeneron

Reuters01-28

** Leerink Partners lowers PT on drugmaker Regeneron Pharmaceuticals REGN.O to $762 from $880; maintains rating of "market perform"

** Brokerage says it lowered 2025 EPS estimates to $40.96 from $44.01 due to REGN's eye drug Eylea franchise pressures and investment spending requirements; analysts on average estimate 2025 EPS to be $44.76, according to data compiled by LSEG

** Leerink notes REGN may face potential pricing pressure on Eylea HD in international markets outside of U.S.

** Last year, REGN reported Q3 sales of $392 mln for higher dose version of Eylea, missing expectations of $417 mln

** Brokerage says it expects REGN to defend its Eylea 2mg market share against Amgen's AMGN.O biosimilar, Pavblu

** Expects U.S. Eylea sales to be constrained due to lack of pre-filled syringe, monthly dosing and RVO indication

** REGN fell 21.3% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2506515247?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-28 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2506515247","market":"us","top_or_hot":-1,"title":"BUZZ-Leerink Partners lowers PT on drugmaker Regeneron","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Leerink Partners lowers PT on drugmaker Regeneron </title></head><body><p>** Leerink Partners lowers PT on drugmaker Regeneron Pharmaceuticals <span>REGN.O</span> to $762 from $880; maintains rating of \"market perform\" </p><p>** Brokerage says it lowered 2025 EPS estimates to $40.96 from $44.01 due to REGN's eye drug Eylea franchise pressures and investment spending requirements; analysts on average estimate 2025 EPS to be $44.76, according to data compiled by LSEG</p><p>** Leerink notes REGN may face potential pricing pressure on Eylea HD in international markets outside of U.S.</p><p>** <span>Last year</span>, REGN reported Q3 sales of $392 mln for higher dose version of Eylea, missing expectations of $417 mln</p><p>** Brokerage says it expects REGN to defend its Eylea 2mg market share against Amgen's <span>AMGN.O</span> biosimilar, Pavblu</p><p>** Expects U.S. Eylea sales to be constrained due to lack of pre-filled syringe, monthly dosing and RVO indication</p><p>** REGN fell 21.3% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Leerink Partners lowers PT on drugmaker Regeneron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Leerink Partners lowers PT on drugmaker Regeneron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-28 21:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nL3N3OO0U0:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-Leerink Partners lowers PT on drugmaker Regeneron ** Leerink Partners lowers PT on drugmaker Regeneron Pharmaceuticals REGN.O to $762 from $880; maintains rating of \"market perform\" ** Brokerage ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nL3N3OO0U0:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001440.SGD","symbol_name":"United Global Dividend Equity Fund A SGD Dist","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nL3N3OO0U0:1","article_id":"2506515247","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2506515247","pubTimestamp":1738071554,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Leerink Partners lowers PT on drugmaker Regeneron ** Leerink Partners lowers PT on drugmaker Regeneron Pharmaceuticals REGN.O to $762 from $880; maintains rating of \"market perform\" ** Brokerage says it lowered 2025 EPS estimates to $40.96 from $44.01 due to REGN's eye drug Eylea franchise pressures and investment spending requirements; analysts on average estimate 2025 EPS to be $44.76, according to data compiled by LSEG** Leerink notes REGN may face potential pricing pressure on Eylea HD in international markets outside of U.S.** Last year, REGN reported Q3 sales of $392 mln for higher dose version of Eylea, missing expectations of $417 mln** Brokerage says it expects REGN to defend its Eylea 2mg market share against Amgen's AMGN.O biosimilar, Pavblu** Expects U.S. Eylea sales to be constrained due to lack of pre-filled syringe, monthly dosing and RVO indication** REGN fell 21.3% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4566":"资本集团","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4599":"减肥药","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4581":"高盛持仓","AMGN":"安进","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4585":"ETF&股票定投概念","BK4211":"区域性银行","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","REGN":"再生元制药公司","BK4534":"瑞士信贷持仓","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4588":"碎股","LU0058720904.USD":"联博国际健康护理基金A","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4589":"SVB概念","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4139":"生物科技","SIVBQ":"硅谷银行","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4207":"综合性银行"},"translate_title":"BUZZ-Leerink Partners降低制药商Regeneron的PT","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SIVBQ":0.9,"AMGN":0.9,"REGN":0.9},"content_text":"BUZZ-Leerink Partners lowers PT on drugmaker Regeneron ** Leerink Partners lowers PT on drugmaker Regeneron Pharmaceuticals REGN.O to $762 from $880; maintains rating of \"market perform\" ** Brokerage says it lowered 2025 EPS estimates to $40.96 from $44.01 due to REGN's eye drug Eylea franchise pressures and investment spending requirements; analysts on average estimate 2025 EPS to be $44.76, according to data compiled by LSEG** Leerink notes REGN may face potential pricing pressure on Eylea HD in international markets outside of U.S.** Last year, REGN reported Q3 sales of $392 mln for higher dose version of Eylea, missing expectations of $417 mln** Brokerage says it expects REGN to defend its Eylea 2mg market share against Amgen's AMGN.O biosimilar, Pavblu** Expects U.S. Eylea sales to be constrained due to lack of pre-filled syringe, monthly dosing and RVO indication** REGN fell 21.3% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2506515247"}